Oleanonic Acid

Oleanonic Acid

SCHEMBL246220

CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 7/20 1.00
PTPN1 P18031 7/20 1.00
F3 P13726 3/20 1.00
PNLIP P16233 1/20 1.00
NOS2 P35228 1/20 1.00
CES1 P23141 4/20 0.76
CES2 O00748 2/20 0.76
RELA Q04206 3/20 0.72
NFKB1 P19838 1/20 0.72
NFKB2 Q00653 1/20 0.72
POLB P06746 3/20 0.71
AKR1B10 O60218 3/20 0.71
GPBAR1 Q8TDU6 3/20 0.71
PSMB11 A5LHX3 2/20 0.71
PSMA7 O14818 2/20 0.71
PLA2G1B P04054 2/20 0.71
PTPRC P08575 2/20 0.71
PTPRF P10586 2/20 0.71
PSMB1 P20618 2/20 0.71
ACP1 P24666 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oleanonic Acid SCHEMBL18687844 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
Oleanonic Acid SCHEMBL18688313 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
Oleanonic Acid SCHEMBL2762433 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
Oleanonic Acid SCHEMBL16175546 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
Oleanonic Acid SCHEMBL12200334 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
Oleanonic Acid SCHEMBL12337276 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
Oleanonic Acid SCHEMBL6898284 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
Oleanonic Acid SCHEMBL12313105 1.00 PTPN2 (1.00) PTPN2PTPN1F3PNLIPNOS2
SCHEMBL17166004 0.92 PTPN1 (0.85) PTPN2PTPN1F3PNLIPNOS2
SCHEMBL16152971 0.89 PTPN1 (0.81) PTPN2PTPN1F3PNLIPNOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731172-A2 COSMETIC COMPOSITION COMPRISING AT LEAST ONE NATURAL RESIN AND A CRYSTALLIZABLE FATTY SUBSTANCE L'OREAL (FR) 2026-04-29 EP claimed
EP-4551300-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2025-05-14 EP claimed
US-20250064716-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2025-02-27 US claimed
WO-2024261287-A2 COSMETIC COMPOSITION COMPRISING AT LEAST ONE NATURAL RESIN AND A CRYSTALLIZABLE FATTY SUBSTANCE L'OREAL (FR) 2024-12-26 WO claimed
EP-4452200-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2024-10-30 EP claimed
WO-2024008771-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2024-01-11 WO claimed
WO-2024008772-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2024-01-11 WO claimed
WO-2024008769-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2024-01-11 WO claimed
WO-2023118430-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN L'OREAL (FR) 2023-06-29 WO claimed
US-20230012268-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2023-01-12 US claimed
US-20130172416-A1 COMPOSITIONS COMPRISING ACIDIC EXTRACTS OF MASTIC GUM REGENERA PHARMA LTD. (IL) 2013-07-04 US claimed
WO-2013101719-A2 AMOORANIN COMPOUNDS AND ANALOGS THEREOF AND RELATED METHODS OF USE NORTHEAST OHIO MEDICAL UNIVERSITY (US) 2013-07-04 WO claimed
CN-103167871-A Composition comprising an acidic extract of mastic gum REGENERA PHARMA LTD 2013-06-19 CN claimed
CN-103013631-A Lubrication ointment NANTONG HUADONG HYDRAULIC & LUBRICATE EQUIPMENT CO LTD 2013-04-03 CN claimed
WO-2012032523-A9 COMPOSITIONS COMPRISING ACIDIC EXTRACTS OF MASTIC GUM REGENERA PHARMA LTD. (IL) 2012-05-03 WO claimed
WO-2012032523-A2 COMPOSITIONS COMPRISING ACIDIC EXTRACTS OF MASTIC GUM REGENERA PHARMA LTD. (IL) 2012-03-15 WO claimed
US-20050238740-A1 Use of mastic and its components for the control of microbial infections THALLIUM HOLDING COMPANY, LLC 2005-10-27 US claimed
EP-1501527-A1 USE OF MASTIC AND ITS COMPONENTS FOR THE CONTROL OF MICROBIAL INFECTIONS LAVIPHARM S.A. (GR) 2005-02-02 EP claimed
WO-2003092712-A1 USE OF MASTIC AND ITS COMPONENTS FOR THE CONTROL OF MICROBIAL INFECTIONS LAVIPHARM S.A. (GR) 2003-11-13 WO claimed
CN-1380302-A Triterpene compound concentrate UNILEVER NV (NL) 2002-11-20 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064716-A1 COSMETIC COMPOSITION COMPRISING A NATURAL RESIN KRT18, CUTA, RARA PTPN2 3309/4885PTPN1 3253/4885F3 698/4885
US-20050238740-A1 Use of mastic and its components for the control of microbial infections CD14, RPL5, NFATC1 PTPN2 2875/4885PTPN1 2641/4885F3 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.